Background. Studies indicate that the prevalence of multidrug-resistant infections, including hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), has been rising. There are many challenges associated with these disease conditions and the ability to develop new treatments. Additionally, HABP/VABP clinical trials are very costly to conduct given their complex protocol designs and the difficulty in recruiting and retaining patients.
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are acute infections occurring in hospitalized patients and are associated with high mortality risk [1] [2] [3] [4] [5] [6] . The public health threat of multidrug-resistant (MDR) bacterial infections is increasing [2, 4, 5, [7] [8] [9] [10] [11] .
New antibiotics are needed to treat MDR bacteria, and several entities are working to increase drug development efforts [12] [13] [14] [15] [16] . However, despite the critical need, biopharmaceutical organization investment in new antibiotics for HABP/VABP and other infectious diseases and new drug approvals has not kept up with the need [17] [18] [19] [20] [21] [22] . Many pharmaceutical companies have chosen to invest in other therapeutic areas such as oncology or endocrinology [23] .
In 2015, 2 independent surveys of pharmaceutical companies were conducted to understand the lack of R&D (research and development) investment [19, 20] . The primary barrier, stated by 80% and 84% of the 2 surveys' respondents, was economic: High costs and low return on investment are major reasons for suspension of antibiotic clinical trial development [19, 20] . Individuals at a 2009 workshop on HABP/VABP clinical trials, cosponsored by the US Food and Drug Administration (FDA) and several professional societies, stated "extraordinarily high costs" as a major challenge and estimated that "recent studies of HABP and/or VABP cost $60 000-$80 000 per patient enrolled [$66 513-$88 684 in 2014 dollars], resulting in phase 3 trial program costs of >$75 million per study [>$82.8 million in 2014 dollars]" [24] [25] [26] .
The survey respondents noted complexity and scientific risk as major barriers in all phases of development with "medical/ scientific reasons" and "unreasonably long recruitment period" as frequent reasons for stopping the clinical development of new antibacterial agents [20] . The 2009 workshop proceedings describe many of the scientific and medical reasons in detail, including challenges in enrolling seriously ill patients in treatment protocols and confounding associated with prior antibiotic exposure [27] . Information from 2 multinational phase 3 HABP/VABP studies also illustrates this operational complexity, in which ≤10% of screened patients met protocol eligibility criteria, and >250 sites were required in 38 countries to enroll >1500 patients over 2.5 years [24] .
To our knowledge, studies identifying key cost drivers of clinical trials have been conducted [28] , but no studies have calculated the specific total cost of HABP/VABP drug development in the United States using a comprehensive cost model to identify opportunities for decreasing overall costs. To address this knowledge gap, we conducted a comprehensive study in 2015 to assess the cost of conducting a phase 3 HABP/VABP clinical trial, compare those costs to phase 3 oncology and endocrine clinical trials, and identify opportunities to lower these costs. The results of this study aim to inform future biopharmaceutical company investment in the development of much-needed antibacterial drugs.
METHODS
We developed a comprehensive cost model estimating the cost of a phase 3 HABP/VABP clinical trial with comparison to phase 3 oncology and endocrine trials. The model was developed by Tufts Center for the Study of Drug Development (CSDD) in partnership with the Clinical Trials Transformation Initiative (CTTI) HABP/VABP Studies Project [29] . A draft of the model was presented for feedback and adjustments at a February 2015 CTTI multi-stakeholder workshop including representatives from drug development companies, the FDA, practicing clinicians from academic medical centers and clinical trial research centers, and patient advocacy groups [30] . HABP/VABP model results were compared with estimates from Oracle Health Sciences ClearTrial Plan and Source Cloud Service under the same clinical trial assumptions to assess validity of the model. The cost model was created in Microsoft Excel 2013 and 2016. Total cost, total cost per patient, and analyses of cost drivers via sensitivity analyses for HABP/VABP, oncology, and endocrine phase 3 clinical trials were calculated from the model.
Clinical Trial Cost Element Selection and Benchmark Data Compilation
We compiled a detailed list all of cost elements prior to creating the model. Cost elements were selected based on institutional knowledge and internal databases, as well as a literature review on clinical trial financial planning models [28, [31] [32] [33] [34] . Costs were classified as being per-patient direct costs, per-trial and per-site direct costs, and per-trial indirect costs. This classification has also been used elsewhere [28] .
We gathered benchmark data to create the cost model, which calculates a fully loaded (direct and indirect) cost profile of a typical phase 3 HABP/VABP, oncology, and endocrine trial. All cost data were inflation-adjusted to reflect 2014 dollars. Data gathered from the Tufts CSDD internal databases are from a number of previous single-and multisponsored studies that collect actual clinical trial data. Commercially available data were selected based on companies that are well established, widely utilized, and offer reputable services. All groups and individuals providing data asked that the data remain confidential.
Per-patient direct costs are defined as study contact costs that vary by the number of patients (eg, cost of patient recruitment, informed consent, and screen fail). Per-patient costs were aggregated into the total per-patient direct cost amount, based on the assumed total number of patients randomized in the trial. Per-trial and per-site direct costs are defined as costs that are attributed to the trial (eg, personnel costs, trial insurance, and cost of electronic data capture). Per-trial indirect costs are not directly attributable to the trial (eg, upper management resource costs, overhead costs). The components within each category were aggregated to derive a total cost for each. Table 1 lists all per-trial and per-site direct costs and per-trial indirect costs included in the model.
Clinical Trial Assumptions and Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Cost Model Sensitivity Analyses

Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial Assumptions
Based on feedback from the ABDD HABP/VABP Studies Team and additional stakeholders, we assumed that a phase 3 HABP/ VABP trial would be conducted in 200 sites and 1000 patients • Screen-fail costs • IMS Health [60] • Screen-fail and randomization rates [35] globally [30] . We also assumed that the randomization rate for HABP/VABP trials is 1 patient randomized per 100 screened based on feedback from the CTTI Workshop and Barriere [24] . Table 2 summarizes all assumptions.
Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial Cost Model Sensitivity Analyses
Changing the following assumptions, we conducted sensitivity analyses to assess the main drivers of the cost model: number of sites, number of patients, procedural cost, screen failure rate, cost of screen fails, and the cost of patient recruitment. Items were selected based on institutional knowledge and recommendations from Knirsch et al and Donnelly et al [36, 37] . See Table 3 for sensitivity analysis details. Sensitivity analyses were conducted separately for each variable as well as by changing 2 assumptions together. Assumptions that were changed together were:
• Scenario 1: Changing the number of sites by 50 sites and changing the number of patients by 200 patients.
• Both assumptions were either increased or decreased together; that is, one assumption was not increased while the other was decreased.
Oncology and Endocrine Phase 3 Clinical Trial Assumptions
For comparison, we assumed that a typical phase 3 oncology and endocrine trial would be conducted in 279 and 123 sites globally, respectively. Assumptions are based on internal Tufts CSDD databases containing clinical trial operations data for oncology and endocrine trials from multiple biopharmaceutical companies conducted as of 2015, and Harper and Li [38] (endocrine only). Table 2 summarizes all assumptions and Figure 1 shows the percentage of sites by therapeutic area and region.
Model without underlying data.xlsx contains the cost model without any underlying proprietary data (see Supplementary Appendix).
RESULTS
Average Cost per Patient for a Typical Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial, Compared to Endocrine and Oncology Trials
We estimate that the overall cost of a phase 3 HABP/VABP clinical trial was $89.6 million overall, and that the overall cost per patient of a phase 3 HABP/VABP clinical trial was $89 600 per patient. By comparison, we estimate that the overall cost of a phase 3 oncology clinical trial was $39.1 million overall, or $87 300 per patient, and that the overall cost of a phase 3 endocrine clinical trial was $33.6 million overall, or $57 700 per patient. As indicated in Table 2 , per patient, phase 3 HABP/ VABP clinical trials were $2200 more expensive than oncology clinical trials and $32 100 more expensive than endocrine trials.
Per-patient direct costs made up the majority of phase 3 HABP/VABP trials, accounting for 74% of overall costs, whereas per-trial direct costs made up the majority of phase 3 oncology and endocrine trials (71% and 74%, respectively).
Using the same assumptions for number of global sites and number of patients, but assuming 43 countries instead of 52, Oracle' s ClearTrial solution also measured the cost of a phase 3 HABP/VABP clinical trial to be approximately $163 million, or $163 000 per patient.
Cost Impact of Changing a Single Model Assumption in a Typical HospitalAcquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial
We estimated the change in overall cost and cost per patient of a typical phase 3 HABP/VABP clinical trial by modifying key assumptions in the model to determine the main cost drivers as described in the methodology. Figure 2 shows the impact of changing each assumption. Changing the screen failure rate yields the largest variation in cost. When decreasing the number of individuals screened from 100 to 90 patients to randomize 1 patient, the cost decreases by approximately $5700 per patient, or $5.7 million overall.
Changing the cost of screen fails yields the second largest variation in cost. When the cost of screen fails is decreased by $60 per patient, the cost decreases by approximately $4200 per patient, or $4.2 million overall.
Changing the number of patients yields the third largest variation in cost. Although the overall cost of the trial increased to $102.8 million, increasing the number of patients to 1200 decreases the cost by approximately $3915 per patient as fixed costs are spread across more patients.
Cost Impact of Changing 2 Model Assumptions in a Typical HospitalAcquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial
We estimated the change in overall cost and cost per patient of a typical phase 3 HABP/VABP clinical trial by modifying multiple key assumptions in the model to determine the main cost drivers as described in the methodology. Figure 3 shows the impact of changing each assumption. Scenario 4 (changing the cost of screen fails by $60 per patient and the screen failure rate by 10 individuals screened to randomize 1 patient) yields the largest variation in cost. When decreasing the cost of screen fails by $60 per patient and decreasing the number of individuals screened from 100 to 90 patients to randomize 1 patient, the cost decreases by approximately $9500 per patient, or $9.5 million overall. Scenarios 1-3 yield similar variations from the baseline estimate of approximately $4300 per patient. Oracle also conducted sensitivity analyses. It found that decreasing the cost of screen fails by $60 and decreasing the number of individuals screened decreases the cost by approximately $16 000 per patient. Oracle's sensitivity analysis of increasing the number of clinical trial sites by 50 and the number of patients by 200 showed an increase in overall trial costs to $195.3 million, which translated to a cost decrease of approximately $318 per patient.
DISCUSSION
We created a fully loaded (direct and indirect) cost model of a typical phase 3 HABP/VABP clinical trial. The overall cost of a phase 3 HABP/VABP clinical trial was calculated to be approximately $89.6 million, or $89 600 per patient (1000 patients in 200 sites). Per patient, phase 3 HABP/VABP clinical trials were $2200 more expensive than oncology trials and $32 100 more expensive than endocrine trials. Sensitivity analyses indicate that the screen failure rate and cost of screen fails are the main cost drivers for phase 3 HABP/VABP clinical trials.
Results from the model corroborate the findings from the 2009 workshop [24] [25] [26] . Our estimates are $6.8 million higher than the 2009 workshop estimate, or $920 higher than the 2009 workshop per-patient maximum. These variations could be due to study assumptions as the manuscripts do not provide detail on how the 2009 workshop estimates were calculated.
Results from our model differ from results from Oracle's analysis by $73 400 per patient. Variations could be attributed to differences in investigator payments for screen failures; Oracle's model used the same cost of screen fails for all countries, whereas our model adjusted this cost by a country deflator. Additionally, Oracle's model measures cost based on hours spent on each activity, calculating 409 464 total hours for the baseline scenario. Our model relies on benchmark data across all disease indications, calculating 106 000 total hours. Although Oracle's ClearTrial tool estimates are greater than our estimates, its sensitivity analyses demonstrate that although increasing the number of patients increases the overall cost of the trial, the cost per patient decreases. A possible explanation for this is that a larger percentage of patients are coming from sites in regions where costs are significantly lower (eg, Eastern Europe and Latin American).
Study results indicate that 75% of HABP/VABP clinical trial costs are attributed to per-patient direct cost variables. This could be explained by the high screen failure rate for HABP/ VABP clinical trials. While the cost of screen failures for infectious disease clinical trials is lower than the cost for screen fails for oncology and endocrine clinical trials, significantly more patients fail screening; for example, to obtain 1000 patients in a HABP/VABP phase 3 trial, 100 000 patients must be screened, thereby increasing the overall cost of screen fails by an order of magnitude. The literature [3, 4, 10, 17, 24-27, 37, 39-57] and sensitivity analyses corroborate this hypothesis, as demonstrated in Figure 2 and Figure 3 . Decreasing both the cost of screen fails as well as the screen failure rate leads to greater decreases in clinical trial costs for HABP/VABP phase 3 clinical trials. This suggests that biopharmaceutical companies and research sites should consider ways to increase the number of potentially eligible patients. The "low-hanging fruit" of streamlining exclusion criteria, to only trial specific essential elements, has mostly been picked. Novel approaches such as using predictive models to find and consent patients earlier in the disease process should be explored [36, 58, 59] . Working to decrease screen failures will have a greater impact on lowering overall costs than trying to streamline already lean clinical trial protocols.
There are some limitations to this study. Assessment of certain variables for sensitivity analyses is limited and, moreover, the model does not account for the risk of needing to hire another contract research organization in cases where additional sites and/or countries are added due to poor enrollment.
Additionally, some cost elements in the model, eg, resource hours and clinical supply costs, are median values across all therapeutic areas and not specific to HABP/VABP, oncology, or endocrinology. Particularly, clinical supply costs are highly variable depending on the drug type, and so the median value may not be generalizable.
With a per-patient price tag of almost $90 000, combined with the potential for low return on investment (ROI), HABP/ VABP trials very well stand to be priced out of the market. Clinical trials of new oncology and endocrine drugs usually enroll outpatient or less acutely ill patients, which may account for the more favorable screening-to-enrollment ratios. In addition, treatment durations for oncology and endocrine drugs are longer and therefore these therapeutic areas have a larger potential for a greater ROI. In comparison, antibacterial drugs have relatively short treatment durations, decreasing the overall ROI. Therefore, it is critically important to investigate and implement ways to improve the feasibility of HABP/VABP trials.
By applying the insights gathered from this cost model, pharmaceutical and biotechnology companies-along with other clinical research stakeholders and programs-can move closer to creating a more efficient and financially viable drug development process for HABP/VABP. Specifically, biopharmaceutical companies, regulatory agencies, and research sites should consider ways to increase the number of potentially eligible patients (ie, decrease screen failures) [36, 58, 59] as an opportunity to decrease HABP/VABP clinical trial costs. This will allow the clinical trials and regulatory communities to address the need for new HABP/VABP antibiotics and provide the medical community with more clinically informative data to aid in treatment of these desperately ill patients.
Notes
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